[1]周鹏飞,董晓琳,查名宝.清肠解毒方联合化疗治疗晚期结直肠癌疗效及对患者预后的影响[J].陕西中医,2024,(9):1226-1229.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.017]
　ZHOU Pengfei,DONG Xiaolin,ZHA Mingbao.Clinical effect and prognosis of Qingchang Jiedu formula combined with chemotherapy in the treatment of patients with advanced colorectal cancer[J].,2024,(9):1226-1229.[doi:DOI:10.3969/j.issn.1000-7369.2024.09.017]
点击复制

清肠解毒方联合化疗治疗晚期结直肠癌疗效及对患者预后的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年9期
页码:
1226-1229
栏目:
临床研究
出版日期:
2024-09-05

文章信息/Info

Title:
Clinical effect and prognosis of Qingchang Jiedu formula combined with chemotherapy in the treatment of patients with advanced colorectal cancer
作者:
周鹏飞; 董晓琳; 查名宝
(芜湖市中医医院,安徽 芜湖 241000)
Author(s):
ZHOU Pengfei; DONG Xiaolin; ZHA Mingbao
(Wuhu Hospital of Traditional Chinese Medicine,Wuhu 241000,China)
关键词:
晚期结直肠癌;  清肠解毒方;  湿热内蕴证;  疗效;  肿瘤标志物;  炎症水平;  预后
Keywords:
Advanced colorectal cancer;  Qingchang Jiedu formula;  Internal dampness-heat accumulation syndrome;  Therapeutic effect;  Tumor marker;  Inflammation level;  Prognosis
分类号:
R 735.3
DOI:
DOI:10.3969/j.issn.1000-7369.2024.09.017
文献标志码:
A
摘要:
目的:研究清肠解毒方与化疗联合治疗晚期结直肠癌(CRC)患者(湿热内蕴型)的临床疗效及对预后的影响。方法:选取晚期CRC患者(湿热内蕴型)67例,分成对照组(n=32)与治疗组(n=35); 对照组采用常规化疗方案,治疗组采用清肠解毒方联合化疗方案; 观察比较两组患者的治疗疗效、肿瘤标志物表达水平、血清因子水平及预后,并统计治疗期间不良反应发生情况。结果:两组总有效率比较差异无统计学意义(P>0.05)。治疗后两组癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原(CA199)表达水平均有所下降,且治疗组下降更明显(P<0.05)。治疗后,两组WBC、PLT、NEUT均有明显降低,与对照组相比,治疗组WBC、PLT下降更少,NEUT下降更多(P<0.05)。随访截至2024年1月,治疗组、对照组中位随访时间为27.3、28.5个月,治疗组OS、PFS均明显高于对照组(P<0.05)。治疗组消化道不良反应、肝肾功能损伤、神经系统毒性发生率更低(P<0.05)。结论:清肠解毒方联合化疗能有效改善晚期CRC患者肿瘤标志物表达水平与血清因子水平,延长OS、PFS,且安全性好,是值得进一步研究应用的治疗方案。
Abstract:
Objective:To observe the clinical effect and prognosis of Qingchang Jiedu formula combined with chemotherapy in the treatment of patients with advanced colorectal cancer(CRC)(internal dampness-heat accumulation syndrome type).Methods:A total of 67 patients with advanced CRC(internal dampness-heat accumulation syndrome type)who underwent chemotherapy were divided into the control group(n=32)and the traditional Chinese medicine group(n=35),the control group were treated with conventional chemotherapy,the traditional Chinese medicine group were treated with self-made Qingchang Jiedu formula combined with chemotherapy.Therapeutic effects,expression levels of tumor markers,serum factor level,and prognosis were observed compared and the incidence of adverse reactions during treatment were statistically analyzed.Results:The total effective rate between the two groups was no significant difference(P>0.05).After treatment,the expression levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199)in both groups decreased,and the levels of traditional Chinese medicine group decreased significantly(P<0.05).After treatment,both groups showed significant reductions in WBC,PLT,and NEUT.Compared with the control group,the traditional Chinese medicine group showed less decrease in WBC and PLT,and more decrease in NEUT(P<0.05).As of January 2024,the median follow-up time of the traditional Chinese medicine group and the control group was 27.3 months and 28.5 months,respectively.OS and PFS of the traditional Chinese medicine group were significantly longer than those of the control group(P<0.05).The incidence rates of gastrointestinal adverse reactions,liver and kidney function damage,and neurological toxicity in the traditional Chinese medicine group were significantly lower(P<0.05).Conclusion:Qingchang Jiedu formula combined with chemotherapy can effectively improve the expression levels of tumor markers and serum factor level,and prolong OS and PFS of patients with advanced CRC,with good safety.

参考文献/References:

[1] 章玉玲,周岳.结直肠癌患者血清循环肿瘤细胞、糖类抗原24-2、糖类抗原19-9水平及其与临床病理特征关系[J].陕西医学杂志,2022,51(3):322-324,329.
[2] 肖鹏,李伟娟,梅家转,等.阿帕替尼联合PD-1单抗后线治疗晚期结直肠癌患者的疗效和安全性[J].实用医学杂志,2023,39(2):255-261.
[3] 胡茜玥,刘正,王锡山.结直肠癌筛查策略的研究现状与思考[J].中国全科医学,2021,24(33):4165-4171.
[4] 郭鹏伟,赵红梅,王毅,等.靶向治疗晚期结直肠癌的疾病控制率、局部有效率研究[J].河北医药,2023,45(13):1995-1997,2001.
[5] 陈华敏,何志军,涂伟,等.XELOX化疗联合肠益方治疗对老年晚期结直肠癌患者生存质量、免疫功能及血浆硫酸类肝素蛋白多糖2、胞裂蛋白9水平的影响[J].临床和实验医学杂志,2023,22(17):1850-1854.
[6] 塔吉姑丽·吐逊,张文定,节阳华.中医药调控中晚期结直肠癌炎性及免疫微环境的研究进展[J].湖南中医药大学学报,2023,43(9):1737-1741.
[7] 汪耔璇,李烜.补中益气汤联合化疗治疗晚期结直肠癌临床研究[J].陕西中医,2020,41(10):1414-1417.
[8] 国家卫生健康委员会.中国结直肠癌诊疗规范(2020版)[J].中华消化外科杂志,2020,19(6):563-594.
[9] 郭振球.实用中医诊断学[M].上海:上海科学技术出版社,2013:213-215.
[10] 丁婕,戴旭,孟宪运,等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(9):1150-1152.
[11] 刘萍,骆学新.肠益方联合XELOX化疗方案对老年晚期结直肠癌患者近期疗效及对血清SDC2、SEPT9和免疫功能的影响[J].中国老年学杂志,2022,42(5):1085-1087.
[12] 郑佳露,郑金洲,顾贤.藤龙补中汤联合化疗治疗晚期结直肠癌疗效研究[J].陕西中医,2023,44(8):1042-1046.
[13] MALKI A,ELRUZ R A,GUPTA I,et al.Molecular mechanisms of colon cancer progression and metastasis:Recent insights and advancement[J].Int J Mol Sci,2021,22(1):130.
[14] 黄浩然,赵杉,王如然,等.扶正消瘤汤对湿热蕴结型晚期结直肠癌术后患者生存率、生活质量及血清白细胞介素6、肿瘤坏死因子α的影响[J].河北中医,2021,43(8):1266-1271.
[15] 张彤,何文婷,陈悦,等.中西医结合治疗对晚期结直肠癌患者生存影响的队列研究[J].北京中医药大学学报,2023,46(3):383-391.
[16] 徐钰莹,杨宇飞,易丹辉.69例晚期结直肠癌患者基因突变特征与中药干预治疗疗效相关性分析[J].世界科学技术-中医药现代化,2023,25(1):286-298.
[17] 孔凡铭,王娜,谢红霞,等.消岩汤联合卡培他滨和贝伐珠单抗在结直肠癌维持治疗中的临床研究[J].中国肿瘤临床,2023,50(10):519-525.
[18] 张强,李会霞,王再见,等.结直肠癌中医证型特点及与粪便SDC2基因甲基化的相关性[J].山东中医杂志,2023,42(3):233-238.
[19] 夏婷婷,王颖.藤梨根从“痰”论治恶性肿瘤的研究进展[J].浙江中医药大学学报,2020,44(7):702-706.
[20] 张换换,陈卓,赵想弟,等.紫草素通过抑制PKM2/PHD3/HIF-1α通路诱导肝癌细胞凋亡[J].南方医科大学学报,2023,43(1):92-98.
[21] 施翠芬,谢斌,张汗顺,等.川楝子配伍对一贯煎抑制荷H22小鼠肝癌细胞增殖的影响[J].世界科学技术-中医药现代化,2022,24(7):2710-2716.
[22] 章玲艳,吴会晨,汪飞,等.参苓白术散加减对结直肠癌患者化疗后骨髓抑制和免疫功能的影响[J].陕西中医,2023,44(8):1086-1089.
[23] 汪倩玲,张逸寅,王华,等.中性粒细胞在肿瘤微环境、肿瘤发生发展及诊治中的作用[J].生理科学进展,2022,53(1):1-6.
[24] 朱巧玲,张荣珍,谢强龙.清肠解毒方对肠癌患者胃肠道功能、生存质量的影响[J].四川中医,2021,39(6):92-95.
[25] 童玫瑰,程千.清肠解毒方对大肠癌术后复发化疗患者肿瘤标记物水平及生活质量的影响[J].陕西中医,2020,41(1):53-56.

相似文献/References:

[1]汪耔璇,李 烜.补中益气汤联合化疗治疗晚期结直肠癌临床研究*[J].陕西中医,2020,(10):1414.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.020]
[2]李振前,杨梦春,刘戎惠,等.扶正消癌汤合四君子汤联合卡培他滨治疗晚期结直肠癌临床研究[J].陕西中医,2022,(8):1037.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.011]
　LI Zhenqian,YANG Mengchun,LIU Ronghui,et al.Effect of Fuzheng Xiaoai decoction and Sijunzi decoction combined with capecitabine on patients with advanced colorectal cancer[J].,2022,(9):1037.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.011]

备注/Memo

备注/Memo:
基金项目:安徽省卫生健康委员会科研项目(AHWJ2022A060)
更新日期/Last Update: 2024-09-09